Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002036
- Lead Sponsor
- Abbott
- Brief Summary
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Univ of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Univ of Minnesota🇺🇸Minneapolis, Minnesota, United States